A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Ranging Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5806 in Subjects less than 24 Months of Age Hospitalized for Respiratory Syncytial Virus (RSV) Related Respiratory Infection

Trial Profile

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Ranging Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5806 in Subjects less than 24 Months of Age Hospitalized for Respiratory Syncytial Virus (RSV) Related Respiratory Infection

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2013

At a glance

  • Drugs Presatovir (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Aug 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 01 May 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 25 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top